Why MediWound Ltd.’s (MDWD) Stock Is Up 5.61%
As of Wednesday, June 24, MediWound Ltd.’s MDWD share price has surged by 5.61%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Commentary & Analysis
Why MediWound Ltd.’s (MDWD) Stock Is Down 6.95%
As of Wednesday, May 27, MediWound Ltd.’s MDWD share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MediWound Ltd.’s (MDWD) Stock Is Down 6.95%
As of Monday, January 12, MediWound Ltd.’s MDWD share price has dipped by 6.95%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MediWound Ltd.’s (MDWD) Stock Is Up 6.12%
As of Wednesday, December 10, MediWound Ltd.’s MDWD share price has surged by 6.12%, which has investors questioning if this is right time to sell.Jenna Brashear
Why MediWound Ltd.’s (MDWD) Stock Is Up 5.48%
As of Monday, December 08, MediWound Ltd.’s MDWD share price has surged by 5.48%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | MDWD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $155.8 | $478.0 | 26% |
|
| Shares Out (Mil) | 13.2 | 42.8 | 25% |
|
| Institutional Ownership | 94.8% | 81.8% | 66% |
|
| Float (Mil) | 8.9 | 44.5 | 18% |
|
| Beta | 0.14 | 0.72 | 10% |
|
| Avg Daily Volume (000s) | 113 | 279 | 38% |
|
| Price Change (52-week) |
(34.8%) | 55.4% | 27% |
|
| Growth | MDWD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (4.9%) | 6.4% | 9% |
|
| Net Income (5yr) | (21.0%) | (2.0%) | 19% |
|
| EPS (5yr) | 2.4% | 15.0% | 35 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.1%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.726) | ($2.230) | ($2.290) | |
| Month Ago EPS | ($0.726) | ($2.230) | ($2.290) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 2 | |
| Three Months Ago EPS | ($0.706) | ($2.385) | ($2.220) | |
| Year/Year Chg | (5.7%) | 6.2% | (40.9%) | |
| Financials | MDWD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $12 | $392 | 10% |
|
| Net Income (TTM) (Mil) | ($20) | ($11) | 24% |
|
| EPS (TTM) | ($1.627) | ($0.700) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | ($7) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($37) | $5 | 22% |
|
| Long-Term Debt (Q1) (Mil) | $9 | $6 | 28% |
|
| Enterprise Value (Q1) (Mil) | $146 | $494 | 24% |
|
| Valuation | MDWD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.37 | 2.04 | 77% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | MDWD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 15.5% | 69.4% | 15% |
|
| Net Margin | (170.1%) | 3.3% | 5% |
|
| ROA | (31.2%) | (22.0%) | 16% |
|
| ROE | (75.4%) | (20.6%) | 11% |
|
| Liabilities to Assets | 50.4% | 32.2% | 43% |
|
| F-Score | 3 | 3 | 18% |
|
MediWound Ltd. did not pass any screens on 10/26/2026.
